3 reports of this reaction
1.7% of all ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE reports
#16 most reported adverse reaction
HAEMATOCHEZIA is the #16 most commonly reported adverse reaction for ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE, manufactured by Bayer HealthCare LLC.. There are 3 FDA adverse event reports linking ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE to HAEMATOCHEZIA. This represents approximately 1.7% of all 179 adverse event reports for this drug.
Patients taking ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE who experience haematochezia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMATOCHEZIA is a less commonly reported adverse event for ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE, but still significant enough to appear in the safety profile.
In addition to haematochezia, the following adverse reactions have been reported for ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE:
The following drugs have also been linked to haematochezia in FDA adverse event reports:
HAEMATOCHEZIA has been reported as an adverse event in 3 FDA reports for ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMATOCHEZIA accounts for approximately 1.7% of all adverse event reports for ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE, making it a notable side effect.
If you experience haematochezia while taking ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.